Revolution Medicines, Inc. is 3.3x more valuable than Krystal Biotech, Inc. by market capitalization ($30.74 B vs $9.21 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KRYS | RVMD |
|---|---|---|
| Market cap | $9.21 B | $30.74 B |
| US-listed rank | #989 | #453 |
| Revenue (latest FY) | $389.13M | $0.00 |
| Net income (latest FY) | $204.83M | -$1.13B |
| Net margin | 52.6% | - |
| P/E (trailing FY) | 45.0 | - |
| SEC filings | 483 | 782 |
Revolution Medicines, Inc. is 3.3x more valuable than Krystal Biotech, Inc. by market capitalization ($30.74 B vs $9.21 B).
In their latest fiscal years, Krystal Biotech, Inc. reported $389.13M in revenue while Revolution Medicines, Inc. reported $0.00.
Full pages: Krystal Biotech, Inc. and Revolution Medicines, Inc., or browse the full rankings.